Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Publisher Correction: Complement-dependent outer membrane perturbation sensitizes Gram-negative bacteria to Gram-positive specific antibiotics.

Heesterbeek DAC, Martin NI, Velthuizen A, Duijst M, Ruyken M, Wubbolts R, Rooijakkers SHM, Bardoel BW.

Sci Rep. 2019 May 21;9(1):7841. doi: 10.1038/s41598-019-43208-4.

2.

Complement-dependent outer membrane perturbation sensitizes Gram-negative bacteria to Gram-positive specific antibiotics.

Heesterbeek DAC, Martin NI, Velthuizen A, Duijst M, Ruyken M, Wubbolts R, Rooijakkers SHM, Bardoel BW.

Sci Rep. 2019 Feb 28;9(1):3074. doi: 10.1038/s41598-019-38577-9. Erratum in: Sci Rep. 2019 May 21;9(1):7841.

3.

Bacterial killing by complement requires membrane attack complex formation via surface-bound C5 convertases.

Heesterbeek DA, Bardoel BW, Parsons ES, Bennett I, Ruyken M, Doorduijn DJ, Gorham RD Jr, Berends ET, Pyne AL, Hoogenboom BW, Rooijakkers SH.

EMBO J. 2019 Feb 15;38(4). pii: e99852. doi: 10.15252/embj.201899852. Epub 2019 Jan 14.

4.

Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models.

Zwarthoff SA, Berends ETM, Mol S, Ruyken M, Aerts PC, Józsi M, de Haas CJC, Rooijakkers SHM, Gorham RD Jr.

Front Immunol. 2018 Jul 23;9:1691. doi: 10.3389/fimmu.2018.01691. eCollection 2018.

5.

Identification of a staphylococcal complement inhibitor with broad host specificity in equid Staphylococcus aureus strains.

de Jong NWM, Vrieling M, Garcia BL, Koop G, Brettmann M, Aerts PC, Ruyken M, van Strijp JAG, Holmes M, Harrison EM, Geisbrecht BV, Rooijakkers SHM.

J Biol Chem. 2018 Mar 23;293(12):4468-4477. doi: 10.1074/jbc.RA117.000599. Epub 2018 Feb 5.

6.

The Staphylococcus aureus polysaccharide capsule and Efb-dependent fibrinogen shield act in concert to protect against phagocytosis.

Kuipers A, Stapels DAC, Weerwind LT, Ko YP, Ruyken M, Lee JC, van Kessel KPM, Rooijakkers SHM.

Microbiology. 2016 Jul;162(7):1185-1194. doi: 10.1099/mic.0.000293. Epub 2016 Apr 25.

7.

Molecular insights into the surface-specific arrangement of complement C5 convertase enzymes.

Berends ET, Gorham RD Jr, Ruyken M, Soppe JA, Orhan H, Aerts PC, de Haas CJ, Gros P, Rooijakkers SH.

BMC Biol. 2015 Nov 9;13:93. doi: 10.1186/s12915-015-0203-8.

8.

Staphylococcus aureus protects its immune-evasion proteins against degradation by neutrophil serine proteases.

Stapels DA, Kuipers A, von Köckritz-Blickwede M, Ruyken M, Tromp AT, Horsburgh MJ, de Haas CJ, van Strijp JA, van Kessel KP, Rooijakkers SH.

Cell Microbiol. 2016 Apr;18(4):536-45. doi: 10.1111/cmi.12528. Epub 2015 Oct 23.

PMID:
26418545
9.

Contribution of the complement Membrane Attack Complex to the bactericidal activity of human serum.

Berends ET, Mohan S, Miellet WR, Ruyken M, Rooijakkers SH.

Mol Immunol. 2015 Jun;65(2):328-35. doi: 10.1016/j.molimm.2015.01.020. Epub 2015 Feb 26.

PMID:
25725315
10.

The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertase.

Woehl JL, Stapels DAC, Garcia BL, Ramyar KX, Keightley A, Ruyken M, Syriga M, Sfyroera G, Weber AB, Zolkiewski M, Ricklin D, Lambris JD, Rooijakkers SHM, Geisbrecht BV.

J Immunol. 2014 Dec 15;193(12):6161-6171. doi: 10.4049/jimmunol.1401600. Epub 2014 Nov 7.

11.

Staphylococcus aureus secretes a unique class of neutrophil serine protease inhibitors.

Stapels DA, Ramyar KX, Bischoff M, von Köckritz-Blickwede M, Milder FJ, Ruyken M, Eisenbeis J, McWhorter WJ, Herrmann M, van Kessel KP, Geisbrecht BV, Rooijakkers SH.

Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13187-92. doi: 10.1073/pnas.1407616111. Epub 2014 Aug 26.

12.

Staphylococcus aureus Staphopain A inhibits CXCR2-dependent neutrophil activation and chemotaxis.

Laarman AJ, Mijnheer G, Mootz JM, van Rooijen WJ, Ruyken M, Malone CL, Heezius EC, Ward R, Milligan G, van Strijp JA, de Haas CJ, Horswill AR, van Kessel KP, Rooijakkers SH.

EMBO J. 2012 Aug 29;31(17):3607-19. doi: 10.1038/emboj.2012.212. Epub 2012 Jul 31.

13.

Staphylococcus aureus virulence is enhanced by secreted factors that block innate immune defenses.

Jongerius I, von Köckritz-Blickwede M, Horsburgh MJ, Ruyken M, Nizet V, Rooijakkers SH.

J Innate Immun. 2012;4(3):301-11. doi: 10.1159/000334604. Epub 2012 Feb 7.

14.

Pseudomonas aeruginosa alkaline protease blocks complement activation via the classical and lectin pathways.

Laarman AJ, Bardoel BW, Ruyken M, Fernie J, Milder FJ, van Strijp JA, Rooijakkers SH.

J Immunol. 2012 Jan 1;188(1):386-93. doi: 10.4049/jimmunol.1102162. Epub 2011 Nov 30.

15.

Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion.

Laarman AJ, Ruyken M, Malone CL, van Strijp JA, Horswill AR, Rooijakkers SH.

J Immunol. 2011 Jun 1;186(11):6445-53. doi: 10.4049/jimmunol.1002948. Epub 2011 Apr 18.

16.

Staphylococcal complement inhibitor modulates phagocyte responses by dimerization of convertases.

Jongerius I, Puister M, Wu J, Ruyken M, van Strijp JA, Rooijakkers SH.

J Immunol. 2010 Jan 1;184(1):420-5. doi: 10.4049/jimmunol.0902865. Epub 2009 Nov 30.

17.

Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor.

Rooijakkers SH, Wu J, Ruyken M, van Domselaar R, Planken KL, Tzekou A, Ricklin D, Lambris JD, Janssen BJ, van Strijp JA, Gros P.

Nat Immunol. 2009 Jul;10(7):721-7. doi: 10.1038/ni.1756. Epub 2009 Jun 7.

18.

Staphylococcal complement evasion by various convertase-blocking molecules.

Jongerius I, Köhl J, Pandey MK, Ruyken M, van Kessel KP, van Strijp JA, Rooijakkers SH.

J Exp Med. 2007 Oct 1;204(10):2461-71. Epub 2007 Sep 24.

19.

Staphylococcal complement inhibitor: structure and active sites.

Rooijakkers SH, Milder FJ, Bardoel BW, Ruyken M, van Strijp JA, Gros P.

J Immunol. 2007 Sep 1;179(5):2989-98.

20.

Early expression of SCIN and CHIPS drives instant immune evasion by Staphylococcus aureus.

Rooijakkers SH, Ruyken M, van Roon J, van Kessel KP, van Strijp JA, van Wamel WJ.

Cell Microbiol. 2006 Aug;8(8):1282-93.

PMID:
16882032
21.
22.

Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases.

Rooijakkers SH, Ruyken M, Roos A, Daha MR, Presanis JS, Sim RB, van Wamel WJ, van Kessel KP, van Strijp JA.

Nat Immunol. 2005 Sep;6(9):920-7. Epub 2005 Aug 7.

PMID:
16086019
23.

Anti-opsonic properties of staphylokinase.

Rooijakkers SH, van Wamel WJ, Ruyken M, van Kessel KP, van Strijp JA.

Microbes Infect. 2005 Mar;7(3):476-84. Epub 2005 Feb 26.

PMID:
15792635
24.

Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis.

van der Flier M, Coenjaerts FE, Mwinzi PN, Rijkers E, Ruyken M, Scharringa J, Kimpen JL, Hoepelman AI, Geelen SP.

J Neuroimmunol. 2005 Mar;160(1-2):170-7.

PMID:
15710470
25.

Vascular endothelial growth factor and blood-brain barrier disruption in tuberculous meningitis.

van der Flier M, Hoppenreijs S, van Rensburg AJ, Ruyken M, Kolk AH, Springer P, Hoepelman AI, Geelen SP, Kimpen JL, Schoeman JF.

Pediatr Infect Dis J. 2004 Jul;23(7):608-13.

PMID:
15247597

Supplemental Content

Loading ...
Support Center